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CardioprotectionCardioprotection, such as preconditioning and postconditioning, has been shown to result in a signiﬁcant
reduction in cell death. Many of the signaling pathways activated by cardioprotection have been elucidated, but
there is still a lack of understanding of the mechanisms by which these signaling pathways reduce cell death.
Mitochondria have been reported to be an important player inmany types of apoptotic and necrotic cell death. If
mitochondria play an important role in cell death, then it seems reasonable to consider that cardioprotective
mechanisms might act, at least in part, by opposing mitochondrial cell death pathways. One of the major
mechanisms of cell death in ischemia–reperfusion is suggested to be the opening of a large conductance pore in
the inner mitochondrial membrane, known as the mitochondrial permeability transition pore. Inhibition of this
mitochondrial pore appears to be one of the major mechanisms by which cardioprotection reduces cell death.
Cardioprotection activates a number of signaling pathways that reduce the level of triggers (reactive oxygen
species and calcium) or enhances inhibitors of the mitochondrial permeability transition pore at the start of
reperfusion. This article is part of a Special Issue entitled: Mitochondria and Cardioprotection.hondria and Cardioprotection.
Building 10, 10 Center Drive,
).
lsevier B.V.© 2010 Published by Elsevier B.V.1. Introduction
Mitochondria are thought to have entered into a symbiotic relation-
ship with cells many millions of years ago. Mitochondria act as the
powerhouse of the cell and supply energy in the form of ATP. However,
mitochondria can also play a destructive role and initiate cell death
pathways or be a ﬁnal effector of cell death. Mitochondria have been
reported to be an important player in many types of apoptotic and
necrotic cell death. If mitochondria play an important role in cell death,
then it seems reasonable to consider that cardioprotective mechanisms
might act, at least in part, by opposingmitochondrial cell death pathways.
2. Cardioprotection
Over the years we have learned a lot about signaling pathways
involved in cardioprotection (see [1–3] for recent reviews). Fig. 1
summarizes current thoughts regarding cardioprotection. Cardioprotec-
tion can occur by signaling pathways initiated prior to or at the beginning
of sustained ischemia (e.g. preconditioning (PC)) and cardioprotection
can also occur by signaling initiated at the very start of reperfusion
(postconditioning). As illustrated in Fig. 1, preconditioning is thought to
lead to releaseof agonists suchas adenosine, bradykinin, or opioids,whichbind to G-protein coupled receptors leading to activation of a signaling
cascade. A number of signalingmolecules have been identiﬁed including:
phosphatidylinositol 3-kinase (PI3K), protein kinase C-epsilon (PKCε),
extracellular regulated kinase (ERK), glycogen synthase kinase-3 beta
(GSK3β), endothelial nitric oxide synthase (eNOS), connexin 43 (Cx43)
and themitochondrial KATP channel [1–6]. P38MAP kinase has also been
suggested to be involved in PC; however its role has been debated [7–9].
The signals generatedareproposed toact on themitochondriawhere they
reduce cell death. Since these signaling pathways signal via phosphory-
lation and nitric oxide, the role of these two post-translational modiﬁca-
tions (PTM) onmitochondrial proteins and function has been extensively
studied. Postconditioning has also been shown to activate some of the
same signaling pathways as preconditioning [2], although there are some
differences in signaling pathways between pre and postconditioning
[10,11].
3. Mitochondria and death
It is commonly hypothesized that cardioprotective signals mediate
protection by acting on the mitochondria to inhibit mitochondrially
mediated cell death [12]. If this hypothesis is correct, an understanding
of the mechanisms of cardioprotection is intimately linked to an
understanding of the mechanisms by which mitochondria regulate cell
death. So what is the role of mitochondria in cell death? The current
hypothesis is that necrotic and some forms of apoptotic cell death
involve prolonged opening of a large conductance pore in the
mitochondria, known as the mitochondrial permeability transition
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Fig. 1. Cardioprotection is typically initiated by activation of G-protein coupled receptors, which result in activation of the PI3K signaling pathway. This leads to phosphorylation and
activation of AKT and eNOS and activation of PKC and ERK (not shown). Activation of the PI3K pathway also leads to phosphorylation and inactivation of GSK. Inhibition of GSK has
been reported to result in a reduction in ATP entry into the mitochondria thus reducing consumption of glycolytically generated ATP, which is consumed by reverse mode of the
F1–F0ATPase. Inhibition of GSK has also been reported to inhibit the MPTP, the precise mechanism is unclear, but inhibition of GSK has been reported to inhibit phosphorylation of
cyclophilin and to correlate with inhibition of MPTP opening. In the ﬁgure p-GSK indicates inactive GSK, which inhibits ATP entry via VDAC and cyclophilin activation of MPTP at least
in part by a decrease in phosphorylation. PKC has also been reported to phosphorylate and inhibit BAD, and to phosphorylate and activate mitochondrial aldehyde dehydrogenase
(not shown). Activation of NOS leads to generation of nitric oxide that in turn activates guanlyly cyclase that has been reported to activate the mitochondrial KATP channel
(not shown). Nitric oxide also leads to protein S-nitrosylation (SNO) and SNO of PTEN results in its inhibition leading to enhanced signaling via PI3K. SNO of the L-type Ca channel
reduces calcium entry resulting in less calcium to enter the mitochondria and thus less calcium activation of the MPTP. SNO inhibits the F1–F0ATPase further reducing consumption
of glycolytic ATP. The reduction in ATP consumption reduces lactate generation and thereby reduces calcium entry via Na–Ca exchange coupled to Na–H exchange. The inhibition of
the F1–F0ATPase also results in a more rapid and complete decline in the mitochondrial membrane potential and since themitochondrial membrane potential is the driving force for
calcium entry into the mitochondrial, this will also reduce mitochondrial calcium. SNO of complex I has been shown to reduce generation of ROS. Thus the cardioprotective signaling
pathways lead to reduction in calcium and ROS triggers for MPTP.
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reported to allow unrestricted movement of solutes of b1.5 kDa. The
MPTP was originally described in the 1970s in studies using isolated
mitochondria in which it was shown that an increase in matrix calcium
results in a change in mitochondrial conformation from the aggregated
to orthodox state and an increase in permeability to sucrose [17–20].
The activation of the MPTP in isolated mitochondria was shown to lead
tomitochondrial swelling andmitochondrial swelling is thus commonly
used as an assay for MPTP opening. These early studies also reported
that the MPTP was sensitive to N-ethylmaleamide (NEM) [20,21]. Over
the ensuing 30 years, a number of activators and inhibitors of MPTP
opening have been described (see [22,23]).
Although initially some thought theMPTPwas a laboratory curiosity,
over thepast decade therehas been renewed interest in theMPTPdue to
studies suggesting that the MPTP is involved in cell death. Table 1
summarizes thedata supporting a role for theMPTP in cell death. Agents
such as cyclosporin, which has been shown to inhibit the MPTP in
isolated mitochondria [24–26], also reduce cell death in the setting of
ischemia reperfusion injury [27–30]. Ablation of cyclophilin D (CypD), a
regulator of the MPTP, reduced infarct size following ischemia
reperfusion and calcium activated MPTP was reduced in CypD−/−Table 1
Data supporting a role for MPTP in I/R death.
Inhibitors reduce I/R death [13,16,27–30,32–34,43,88]
Cyclosporin [27–30,43,88]
Cyclophilin D knockout [13,16]
Low reperfusion pH [32–34]
Reduction in MPTP with cardioprotection [44,89–92]
Reduction in MPTP activators is protective [46,50,66,70,93–96]
Calcium [46,50,93–95]
ROS [66,70,96]mitochondria [13,16]. Many factors (high matrix calcium, reactive
oxygen species (ROS), and high inorganic phosphate), which have been
shown to be activators of MPTP [15,22], are present at the start of
reperfusion. Low pH has also been shown to inhibit MPTP opening [31].
It is proposed that the low pH during ischemia keeps the MPTP closed,
but that restoration of intracellular and matrix pH at the start of
reperfusion, in the presence of other activators of MPTP, results in
sustained opening of MPTP. Low pH at the start of reperfusion can
reduce ischemia–reperfusion mediated death [32–34].
In spite of the large amount of interest in theMPTP and its apparent
importance in cell death, its molecular identity is unknown. Obviously
the lack of knowledge of themake-up of theMPTP is a serious limitation
to our understandingof this aspect of cell death. Itwasproposed that the
MPTP was formed by some conformational change in the association of
adenine nucleotide translocator (ANT) and voltage dependent anion
channel (VDAC) contact sites between the inner and outer mitochon-
drial membranes. Based on the observation that cyclosporin could
inhibit the MPTP by its binding to cyclophilin D [24–26], cyclophilin D
was usually placed as a regulator of the MPTP. In support of a role for
ANT, inhibitors of ANT can both activate and inhibit MPTP [35].
Cyclophilin Dwas also reported to bind to ANT, although it has recently
been suggested that this may be an artifact based on a non-speciﬁc
antibody and that the phosphate carrier might be the target of
cyclophilin D detected by this antibody [36]. However, recent studies
have shown that genetic ablation of either ANT [37] or VDAC [13,38]
isoforms did not eliminate the MPTP, suggesting that neither of these
proteins is an obligatory component. Ablation of cyclophilin D did
reduce ischemia–reperfusion induced cell death, suggesting a role for
cyclophilin in activating the MPTP [13,16]. Recently Halestrap and
coworkers have proposed that the phosphate carrier is a critical
component of the MPTP and that the interaction between ANT and
the phosphate carrier can modulate MPTP opening [36,39]. They show
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inhibitors of theMPTP (NEM and ubiquinone analogues) have a similar
concentration dependent inhibition of phosphate transport. An alter-
native proposed by He and Lemasters suggests that oxidized proteins
may misfold in the inner membrane leading to an unregulated channel
such as the MPTP [40]. It is suggested that this might explain why
ablation of one protein does not lead to loss of MPTP, because other
oxidized proteins can take their place. A composite hypothesiswould be
that there is a preferred molecular composition of the MPTP, but if this
preferred composition is absent due to genetic deletion of one of the
components, other proteins can misfold, leading to a delay in MPTP
opening but not permanent elimination of the channel.
The MPTP is a channel in the inner mitochondrial membrane so it
seems likely that it involves some inner mitochondrial protein that can
span the membrane. This group would include all the inner membrane
channels and transporters, suchas theANT, thePi carrier, the glutamate-
aspartate carrier, the calcium uniporter, Carnitine palmitoyltransferase
1 (CPT-1), the Na–calcium exchanger, Cx 43, etc. It would also include
many of the components of the electron transport chain such as the
F1–F0ATPase. Recently Bernardi and coworkers have reported that
cyclophilin can bind to components of the stalk of the F0ATPase in a
phosphate dependent manner [41]. Thus there are a large number of
potential candidates. However, Brookes et al. have recently reported
that uncouplingprotein 2 (UCP2) does not appear to serve asMPTP [42].
One challenge is that many mitochondrial channels and transporters
have yet to be identiﬁed at the molecular level. Based on the inhibitor/
activator data the MPTP (or its regulator) is likely to be sensitive to
cyclosporin, calcium,NEM, ROS, Pi, pH, andNADH. However it is unclear
which effects are attributable to the MPTP itself, and which are due to
regulators of the pore.
4. How might cardioprotection reduce cell death?
If we assume that activation of the MPTP is the cause of cell death,
then how do cardioprotective signals reduce MPTP opening? There
are two general mechanisms by which PC might reduce MPTP. PC
could act directly on the MPTP to inhibit its opening or PC could
reduce the level of triggers of MPTP such as calcium or ROS. These two
possibilities are not mutually exclusive and both may contribute.
4.1. PC reduces levels of triggers of MPTP
MPTP has been shown to open at the start of reperfusion [2,43–45]
and its opening is generally attributed to an increase inmatrix calcium
and/or ROS. It is therefore possible that cardioprotective signaling
works by reducing matrix calcium and/or ROS, rather than by direct
modulation of MPTP components. What are the main sources of the
rise in matrix calcium and ROS generation at the start of reperfusion?
We will discuss these separately.
4.1.1. Calcium
It has been shown that PC and other models of cardioprotection
reduce the rise in cytosolic calciumduring ischemia ([46–48]). There are
several mechanisms (reviewed in Fig. 1) by which PC is proposed to
reduce the rise in cytosolic calcium during ischemia and early
reperfusion. As reviewed elsewhere, during ischemia, there is a rise in
cytosolic sodiumdue to a combination of Na entry via persistent sodium
channels and Na–H exchange [49]. This rise in sodium results in a rise in
calcium via the plasma membrane Na–Ca exchanger. Calcium can also
enter the cell via the L-type calcium channel [50]. The rise in
mitochondrial matrix calcium at the start of reperfusion can be
attributed to a rise in Cai that occurs during ischemia as well as at the
start of reperfusion.Re-oxygenation at the start of reperfusionallows re-
energization of the mitochondria, and restoration of membrane
potential, which is the driving force for calcium uptake into the matrix.
Thusmitochondria can be amajor sink for the rise in cytosolic calciumatthe start of reperfusion. In the next sectionwewill discuss howPCmight
alter mechanisms responsible for the rise in matrix calcium.
4.1.1.1. PC can reduce the rise in calciumvia the sodium–calciumexchanger
(NCX). PC has been shown by a number of investigators to mildly reduce
ischemic acidiﬁcation [47,51]. This could conceivablymake theopeningof
the MPTP more likely during ischemia, but the reduction in ischemic pH
with PC is small (~0.3–4 pH units) and so the pH is still in the range to
inhibit theMPTP.However the reduction inhydrogen ionduring ischemia
would reduce the I/R induced rise in sodium via the sodium–proton
exchanger (NHE). It has been suggested that a rise in sodium occurs
during ischemia and early reperfusion as a result of a combination of
Na–H exchange and Na entry via persistent Na channels (see [49]). This
increase in sodiumwill serve as the driving force for reversemodeNa–Ca
exchange resulting in calcium entry into the cytosol. Normally calcium is
extruded frommyocytes byNCX operating in the forwardmode (calcium
extrusionmode)using theNagradient as adriving force. Asmentioned, at
the start of ischemia, the sodium gradient is reduced and NCX now
functions to allow an increase in intracellular calcium. The plasma
membrane Ca ATPase is a low capacity transporter and it is likely to be
inhibited due to low ATP during ischemia, so it only slowly reduces this
rise in cytosolic calcium. Inhibitors of the rise in sodium during ischemia
and reperfusion have been shown to reduce ischemia–reperfusion injury
(see [49] for discussion). PC has been shown not only to reduce ischemic
acidosis and/or lactate production, but it has also been shown to reduce
the rate of decline in ATP [47,52]. The combination of reduced lactate
production coupled with a reduced rate of fall in ATP suggests that PC
reduces the rate of ATP breakdown [52]; themechanisms responsible are
unclear, but one hypothesis is that PC by several possible mechanisms
might slowthe rate of the reversemodeof the F1–F0ATPase.Normally the
protons that are extruded from the matrix during electron transport re-
enter the matrix via the F1–F0ATPase and the energy of this reaction is
used to drive the synthesis of ATP. However, during ischemia when
electron transport is blocked due to lack of oxygen, the mitochondrial
membrane potential declines and the F1–F0ATPase can run in reverse,
becoming a consumer of ATP [53,54]. The energy from ATP consumption
is used to generate or attenuate the fall in mitochondrial membrane
potential [55]. It had been proposed that PC might directly inhibit the
reversemode of the F1–F0ATPase bymore rapid binding of the inhibitory
factor (IF); however measurements of F1–F0ATPase activity in PC hearts
showed no difference in activity [56,57]. However, Sun et al. have
reported that PC results in S-nitrosylation (SNO) of the F1–F0ATPase,
which in turn inhibits its activity [58]. SNO is a labilemodiﬁcation and it is
lost during isolation of mitochondria unless care is taken to retain it
(e.g. samples are kept in the dark andmetals are chelated). Furthermore,
SNO is shown to be rapidly reversedduring reperfusionmaking it an ideal
modiﬁcation for temporary inhibition of the F1–F0ATPase. Das et al. have
also reported that PC mediated inhibition of GSK results in a decrease in
phosphorylation of the VDAC which results in decreased ATP entry into
the matrix via VDAC [59]. During ischemia, ATP is primarily generated in
the cytosol via anaerobic glycolysis. This glycolytic ATP can then enter the
mitochondria via VDAC and the ANT where it can be consumed by the
reversemode of the F1–F0ATPase. Thus inhibition of F1–F0ATPase and/or
ATP entry via VDAC would result in a decrease in the rate of ATP
breakdown during ischemia and would reduce generation of protons
during ischemia. It has alsobeen suggested that PC can lead to ametabolic
slowdownwith a slowwake-up [60]. The exactmechanism for this is still
somewhat unclear, but it is interesting that many components of the
electron transport chain are modiﬁed by PC and other cardioprotective
mechanisms.
4.1.1.2. PC can reduce calcium entry via the L-type Ca channel. Wehave
found that PC and other forms of cardioprotection can lead to
S-nitrosylation of the L-type Ca channel, which in turn reduces the
activity of the L-type Ca channel and thereby reduces calcium entry
during ischemia [58,61]. Consistent with this hypothesis, activation of
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death [50], and inhibition of this channel is protective.
4.1.1.3. PC can activate sarcoplasmic–endoplasmic reticulum Ca ATPase
(SERCA). The calcium uptake and release mechanisms of the sarcoplas-
mic reticulum (SR) are also frequently disrupted during ischemia–
reperfusion. Given the close localization of themitochondria and the SR,
altered SR calcium handling can lead to alterations in mitochondrial
calcium (see [62]). Consistent with a role for SR calcium handling,
increasing the expression of SERCA2a has been shown to reduce infarct
size [63]. SERCA is also activated by S-nitrosylation [58].
Taken together, the PC mediated reduction in calcium entry via the
plasma membrane NCX and the L-type Ca channel and the increase in
calcium uptake into the SR result in less calcium available for transport
into thematrixwhere it can activate theMPTP. Interestingly, Grifﬁths et
al. [64] have reported a rise in matrix calcium during ischemia that is
suggested to occur due to calcium inﬂux into the matrix on the
mitochondrial NCX. Under normal conditions the electrogenic mito-
chondrial NCX primarily extrudes calcium from the matrix. However,
during ischemia when the mitochondrial membrane potential is lost,
NCX can lead to an increase in matrix calcium as indicated by the lower
matrix calcium during ischemia in the presence of CGP37157, an
inhibitor of mitochondrial NCX.
4.1.2. Reactive oxygen species (ROS)
Along with calcium, an increase in ROS is thought to be a primary
activator of theMPTP at the start of reperfusion [65,66]. One protective
effect of PC is to reduce ROS production at the start of reperfusion [67].
What are some of the targets of PC that might reduce ROS generation?
It is generally thought that ROS generation at the start of reperfusion is
primarily mediated by enhanced electron leak in the electron
transport chain due to oxidative damage that occurs during ischemia.
It has also been suggested, andwe have obtained some data to support
the concept, that PCmight lead to increased SNOof proteins thatmight
protect them from oxidation [58]. We have identiﬁed [68] several
proteins that show increased SNO and decreased oxidation during
ischemia and reperfusion. It is interesting to speculate that PC
mediated SNO of these proteins protects them from oxidation and
thereby reduces ROS generation at the start of reperfusion. Complex I
and complex III are thought to be important sources for ROS
production. Brookes and coworkers have reported that PC results in
SNO of complex I which reduces ROS generation during ischemia [69].
ROS generationbymonoamine oxidase and shc66has also been shown
to play a role in ROS generation during ischemia and reperfusion
[66,70]. In addition to the electron transport chain, it is becoming clear
that lipoamide containing dehydrogenases such as pyruvate dehydro-
genase (PDH) and alpha-ketoglutarate dehydrogenase (αKGDH) can
be an important contributor to ROS production [71]. SNO and
phosphorylation of PDH and αKGDH have been reported to occur
with PC [58]; it will be important to establish whether these PTM
protect these enzymes from oxidation and if they contribute to
reduced ROS generation in PC heart.
4.2. PC acts directly on the MPTP to inhibit its opening
If cardioprotective signaling pathways protect by direct inhibition
of MPTP, then one would expect that these signaling pathways would
modify or alter components or modulators of the MPTP. If this is the
case one might expect cardioprotective signaling to result in post-
translational modiﬁcations in mitochondrial proteins that are part of
the MPTP. Unfortunately the components of the MPTP have not been
identiﬁed so there are no clear targets to evaluate for post-
translational modiﬁcations. Thus there are two approaches that one
can take to begin to examine whether cardioprotection might alter
putative MPTP components. One can take a candidate approach and
examine whether cardioprotection results in alterations in proteinsthat are suggested to be part of the MPTP. Alternatively one can
employ unbiased approaches to see if they provide common changes
in proteins andmight thus provide insight into possible candidates for
the MPTP. In either approach, it is useful to consider what criteria one
might use in selecting candidates. Genetic ablation of cyclophilin D
signiﬁcantly reduced MPTP opening [13,16], and addition of cyclos-
porin acutely inhibits the MPTP [24,26,27]. Thus it is generally
assumed that cyclophilin D is likely to bind to at least some of the
components of the MPTP. The MPTP has also been shown to be
sensitive to NEM and other cysteine modifying agents, so it is likely
that theMPTP contains reactive cysteine residues [21,36]. TheMPTP is
an inner membrane permeability, so it is also likely that the
candidates will span the inner membrane.
4.2.1. Candidate approach
The problem with the candidate approach is that the putative
components of MPTP are unknown. PC mediated modiﬁcations in
VDAC and ANT were examined based on the rationale that they were
components of the MPTP [72]; however genetic studies have
suggested that they are not required MPTP components [37,38,73].
Until the components of the MPTP are identiﬁed it may be difﬁcult to
address whether cardioprotection results in alteration in MPTP
components. However, cyclophilin D has been shown to be a regulator
of the MPTP, and recent data suggest that GSK can phosphorylate
cyclophilin D leading to activation of MPTP [74]. These data are
consistent with the observations that cardioprotection is associated
with inhibition of GSK [75–77].
4.2.2. Unbiased proteomic approach
One might consider an alternative approach, that is, using
unbiased proteomic approaches to see if alterations in mitochondrial
proteins that occur with cardioprotection might provide some insight
into components of the MPTP. Indeed, several groups have taken the
approach of identifying mitochondrial proteins that are modiﬁed by
cardioprotection. Arrell et al. examined the effects of the cardiopro-
tective drugs adenosine and diazoxide on the proteome using 2D gel
electrophoresis [78]. Arrell et al. found consistent differences in 28
protein spots that represented 19 non-redundant proteins in hearts
treated with cardioprotective drugs [78]. Adenosine and diazoxide
both resulted in an increase in amounts of isocitrate dehydrogenase,
NADH ubiquinone oxidoreductase subunit 23 and subunit 24, ATP
synthase gamma, and DJ-1 antioxidant protein. Adenosine and
diazoxide both resulted in a decrease in metaxin 2. Adenosine and/
or diazoxide also resulted in post-translational modiﬁcation (PTM) of
four proteins, but only ADP ribosyl hydrolase showed PTM with both
adenosine and diazoxide.
Wong et al. [79] also studied changes in mitochondrial proteins in
the setting of cardioprotection. They used proteomics to examine
mitochondrial protein levels/post-translational modiﬁcations that
were common between two models of cardioprotection, PC and
treatment with GSK inhibitors. These studies were done in a
Langendorff perfused heart model. Levels of cytochrome c oxidase
subunits Va and VIb, ATP synthase-coupling factor 6, and cytochrome
b-c1 complex subunit 6 were increased while cytochrome c was
decreased in PC and GSK inhibition. Furthermore, with PC and GSK
inhibitor treatment, the amount of cytochrome c oxidase subunit VIb
was found to be increased in mitochondrial supercomplexes, which
are comprised of complexes I, III, and IV. This result would suggest
that changes in complex subunits associated with cardioprotection
may affect supercomplex composition.
Feng et al. [80] reported that isoﬂurane mediated cardioprotection
was associated with phosphorylation of the adenine nucleotide
translocator on Tyr 194. Mayr et al. [81] examined proteomic
differences in mice with constitutively active PKCε. Hearts from
mice with constitutively active PKCε exhibit smaller infarcts than WT
littermates. Compared to control and hearts with dominant negative
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et al. found differences in only 2 mitochondrial proteins (mitoﬁlin and
manganeses SOD) in hearts frommicewith constitutively active PKCε.
In contrast to these studies Clarke et al. [82] reported that PC
resulted in no signiﬁcant changes in phosphorylation of the
mitochondrial proteome, although they did ﬁnd changes in carbon-
ylation. It should be noted that in the study by Clarke et al., the
mitochondria were highly puriﬁed. Such puriﬁcation is important if
one wants to establish the mitochondrial location of a protein.
Phosphorylation and other post-translational modiﬁcations could be
lost during the puriﬁcation. This difference might account for some of
the differences observed in post-translational modiﬁcation of proteins
associated with cardioprotection. However, they did observe phos-
phorylated mitochondrial proteins, just no change with PC. It is
possible the PC mediated phosphorylation is dynamic and quickly lost
during the isolation and puriﬁcation procedure. Additional studies
will be needed to resolve this issue.
SNO of several mitochondrial proteins has also been shown with
cardioprotection [83,84]. SNO is the addition of a nitric oxide group to
cysteine groups in proteins (see [84] for a review). An increase in
nitric oxide, as has been shown to occur during PC [85–87], would
lead to an increase in SNO. The increase in nitric oxide during PC
appears to be due to both an increase in NOS activity as well an
increase in non-enzymatic production likely via breakdown of nitrite.
Interestingly MPTP appears to have several important cysteine
residues and is blocked by low levels of NEM [21]. Depending on
the nitric oxide level, SNO might react with these cysteines and
regulate MPTP activity. Furthermore, SNO is rapidly reversible so that
changes would be rapidly reversed on reperfusion. Sun et al. reported
that cardioprotection by PC or GSNO treatment resulted in an increase
in SNO of several mitochondrial proteins including complex I (75 kDa
subunit), F1–F0ATPase alpha 1 subunit, creatine kinase, acyl CoA
dehydrogenase, alpha ketoglutarate dehydrogenase and malate
dehydrogenase [58]. Brookes and coworkers showed that PC results
in SNO of complex I which they suggest results in less ROS generation
in the setting of ischemia and reperfusion [69].
So a number of proteomic changes associated with cardioprotec-
tion have been described. Do these changes provide any insight into
mechanisms by which cardioprotection might reduce MPTP opening
or provide any insight into the identity of the MPTP? A number of
changes in mitochondrial proteins have been associated with
cardioprotection; however there are no clear consistent changes
that suggest an obvious target. It should be noted that due to dynamic
range issues, proteomic methods tend to select for high abundance
proteins. Thus if the MPTP is a low abundance protein, or if reduced
MPTP in cardioprotection is due to alteration in a low abundance
regulatory protein, changes in this protein might not be consistently
observed in these proteomic studies. Also with the 2D gel methods
used in the studies by Arrell et al. andWong et al., membrane proteins
are frequently not well resolved. It appears that although general
proteomic methods provide information on changes associated with
cardioprotection, at present these methods provide no clear consen-
sus regarding the identity of the MPTP. However, newer quantitative,
direct mass spectrometry approaches are identifying more low
abundance proteins and these newer proteomic approaches may
provide insight into the elusive MPTP.
5. Summary and future perspective
Cardioprotection activates a number of signaling pathways that
reduce the level of triggers or enhances inhibitors of the MPTP at the
start of reperfusion. This appears to be one of themajor mechanisms by
which cardioprotection such as PC reduces cell death. PC has been
shown to reduce ROS, calcium and Pi (activators ofMPTP) at the start of
reperfusion. This hypothesis suggests that PC protects by acting on
multiple targets rather than by acting via a linear pathway that leads tooneﬁnal target.Many of the inhibitors such as inhibitors of PKCε or PI3K
appear to act early in the signaling cascade and it appears that PI3K and
PKCε activation result in changes inmany of the downstreampathways.
It is also possible that PC might alter the activity of the MPTP
(either directly or via some regulatory protein). However, given the
paucity of informationabout the identity of theMPTP, it is not possible at
the present time to determine whether cardioprotection can more
directly alter the activity of the MPTP. Thus a major area for future
research needs to be directed to identifying the MPTP.References
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